FERRIPROX Drug Patent Profile

Which patents cover Ferriprox, and when can generic versions of Ferriprox launch?

Ferriprox is a drug marketed by Chiesi and is included in three NDAs. There are seven patents protecting this drug and one Paragraph IV challenge.

This drug has sixty-two patent family members in thirty-four countries.

The generic ingredient in FERRIPROX is deferiprone. There are four drug master file entries for this compound. Four suppliers are listed for this compound. Additional details are available on the deferiprone profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Ferriprox

A generic version of FERRIPROX was approved as deferiprone by TARO on February 8^th, 2019.

Summary for FERRIPROX

International Patents:	62
US Patents:	7
Applicants:	1
NDAs:	3
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	91
Clinical Trials:	26
Patent Applications:	2,803
Drug Prices:	Drug price information for FERRIPROX
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for FERRIPROX
What excipients (inactive ingredients) are in FERRIPROX?	FERRIPROX excipients list
DailyMed Link:	FERRIPROX at DailyMed

See drug prices for FERRIPROX

Recent Clinical Trials for FERRIPROX

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Chiesi Canada Corp	Phase 4
Hadassah Medical Organization	Phase 2/Phase 3
SocraMetrics GmbH	Phase 1

See all FERRIPROX clinical trials

Pharmacology for FERRIPROX

Drug Class	Iron Chelator
Mechanism of Action	Iron Chelating Activity

Paragraph IV (Patent) Challenges for FERRIPROX

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
FERRIPROX	Tablets	deferiprone	500 mg	021825	1	2016-01-29

US Patents and Regulatory Information for FERRIPROX

FERRIPROX is protected by seven US patents and five FDA Regulatory Exclusivities.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Chiesi	FERRIPROX	deferiprone	SOLUTION;ORAL	208030-002	Apr 20, 2018		DISCN	Yes	No	8,703,156		Y
Chiesi	FERRIPROX	deferiprone	TABLET;ORAL	212269-001	May 19, 2020		RX	Yes	Yes
Chiesi	FERRIPROX	deferiprone	TABLET;ORAL	212269-001	May 19, 2020		RX	Yes	Yes	11,723,874

Expired US Patents for FERRIPROX

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Chiesi	FERRIPROX	deferiprone	TABLET;ORAL	212269-001	May 19, 2020	7,049,328
Chiesi	FERRIPROX	deferiprone	SOLUTION;ORAL	208030-002	Apr 20, 2018	7,049,328
Chiesi	FERRIPROX	deferiprone	TABLET;ORAL	021825-001	Oct 14, 2011	7,049,328

EU/EMA Drug Approvals for FERRIPROX

Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
Chiesi Farmaceutici S.p.A.	Ferriprox	deferiprone	EMEA/H/C/000236Ferriprox monotherapy is indicated for the treatment of iron overload in patients with thalassaemia major when current chelation therapy is contraindicated or inadequate.Ferriprox in combination with another chelator is indicated in patients with thalassaemia major when monotherapy with any iron chelator is ineffective, or when prevention or treatment of life-threatening consequences of iron overload (mainly cardiac overload) justifies rapid or intensive correction.	Authorised	no	no	no	1999-08-25
Lipomed GmbH	Deferiprone Lipomed	deferiprone	EMEA/H/C/004710Deferiprone Lipomed monotherapy is indicated for the treatment of iron overload in patients with thalassaemia major when current chelation therapy is contraindicated or inadequate.Deferiprone Lipomed in combination with another chelator is indicated in patients with thalassaemia major when monotherapy with any iron chelator is ineffective, or when prevention or treatment of life-threatening consequences of iron overload justifies rapid or intensive correction.	Authorised	yes	no	no	2018-09-19

International Patents for FERRIPROX

See the table below for patents covering FERRIPROX around the world.

Country	Patent Number	Title	Estimated Expiration
Austria	427107
Australia	2001270402
Australia	7040201

Last updated: July 28, 2026

Ferriprox (deferiprone) market dynamics and financial trajectory: revenue, pricing, exclusivity, and competitive risks

Ferriprox (deferiprone) is a branded, off-patent oral iron chelator used primarily in transfusional iron overload (notably thalassemia and other chronic transfusion-dependent anemias). The revenue trajectory has been shaped by (1) patent and exclusivity cliffs by jurisdiction, (2) the consolidation of major marketing rights through licensing structures, (3) generic and follow-on competition patterns that vary by market approval status and bioequivalence acceptance, and (4) ongoing label and positioning competition versus deferasirox and deferoxamine. As the brand matures, growth increasingly depends on country-by-country uptake, switching from other chelators, and procurement dynamics in specialty infusion and hematology pathways.

What is Ferriprox’s current market position and where does revenue concentrate?

Bottom line: Ferriprox revenue is concentrated in markets where (a) oral chelation is adopted for chronic transfusional iron overload, (b) national reimbursement supports iron chelation, and (c) competing products face formulary or cost constraints.

Key market-position drivers:

• Therapeutic usage: Ferriprox is used for chronic iron overload in patients with thalassemia syndromes receiving transfusions and in other approved settings depending on jurisdictional labeling.
• Clinical differentiation: Oral dosing and long clinical history support clinician familiarity, which can slow switching to alternatives once a patient is established on therapy.
• Reimbursement and procurement: Hematology centers and national reimbursement policies often decide utilization more than head-to-head marketing.
• Supply and manufacturing continuity: Consistent supply impacts specialty prescribing where missed doses can drive therapy changes.

Revenue concentration patterns typically track:

• EU and UK hematology reimbursement frameworks
• MENA and select APAC markets with established chelation programs
• Countries where Ferriprox is preferred or where generic erosion is limited due to approval/launch timing

How has Ferriprox revenue trended over time and what financial phases show up in the cycle?

Bottom line: Ferriprox follows a typical branded specialty cycle: initial growth after broad uptake, then plateau, then step-down in markets where generics enter, offset partly by expansion into additional indications and geographies.

Financial phases:

1. Adoption and formulary build (growth/plateau phase)
   • Expansion in transfusion-dependent patient populations
   • Increased prescriber comfort with oral chelation
   • Reimbursement approvals and hospital formularies
2. Stability phase
   • Patient retention
   • Ongoing procurement contracts and treatment pathways
3. Erosion phase
   • Entry of generics and authorized generics
   • Price pressure from competing oral chelators
4. Repositioning phase
   • Segmenting by patient subtypes, physician preference, and regional guideline emphasis
   • Competitive differentiation versus deferasirox (oral, once-daily) and deferoxamine (parenteral)

Which market dynamics most affect Ferriprox financial performance: pricing, reimbursement, and switching?

Bottom line: Pricing pressure and payer reimbursement rules are the dominant drivers, with switching influenced by dosing convenience and clinical handling rather than brand differentiation alone.

Major dynamics:

• Net price compression: Specialty drugs in iron chelation face frequent tender-based procurement and periodic price negotiations.
• Formulary substitution: Once a cheaper alternative is available, formularies can force payer-driven switching.
• Patient-level inertia: Established patients often remain on therapy, which delays revenue loss after generic availability.
• Therapy switching triggers:
  • Safety monitoring requirements
  • Tolerability and adherence
  • Local availability and procurement pricing

How does Ferriprox compete against deferasirox (Exjade/Jadenu) and deferoxamine on market share?

Bottom line: Ferriprox competes mainly as an oral chelator alternative, while deferasirox often captures preference for regimen simplicity. Ferriprox sustains share where clinicians prioritize its clinical profile or where payers steer to it based on cost and access.

Comparison points that affect market share:

• Administration: Ferriprox is oral but typically requires multiple daily dosing, which can reduce convenience versus once-daily deferasirox.
• Safety monitoring and practice patterns: Iron chelation requires ongoing monitoring. Practice patterns and center protocols can preserve Ferriprox usage in established cohorts.
• Payer behavior: In procurement-driven systems, deferasirox may win on tender price, but Ferriprox can retain share where contracts or reimbursement favor it.

What patent and exclusivity cliffs matter for Ferriprox market economics by jurisdiction?

Bottom line: The financial trajectory is sensitive to when each country’s branded exclusivity ends and when generics gain approval and launch.

Exclusivity and patent-impact channels:

• Primary drug substance and composition-of-matter: Typically expire first, enabling generic entry for the API depending on follow-on patent coverage.
• Formulation and dosing patents: Can delay generic substitution if they cover specific product characteristics.
• Method-of-use patents: Can constrain marketing for certain indications or patient populations.
• Regulatory exclusivity: Data exclusivity and market exclusivity mechanisms can delay generic approval even after patent expiry.

Because Ferriprox is a legacy product with long market history, most core exclusivity has likely moved past in major markets, leaving the remaining financial lever to be follow-on patent coverage and the pace of generic approvals and tender wins.

What formulations are protected or can generics copy for Ferriprox tablets and oral solution?

Bottom line: Generic entry risk depends on whether follow-on patents cover product-specific features like dosage forms, excipients, stability, and bioequivalence-enabling parameters.

Key formulation IP risk areas:

• Oral liquid manufacturing and stability: Oral solution products can have distinct formulation IP barriers (where covered).
• Dosage unit and particle profile: Tablet formulations can carry IP around composition and processing.
• Manufacturing method patents: Some secondary patents can be difficult to design around without licensing.

When do generics and Paragraph IV challenges become relevant for Ferriprox?

Bottom line: Paragraph IV challenges apply in the US Hatch-Waxman framework for ANDA products against Orange Book-listed patents. For Ferriprox, the practical question is not whether challenges exist, but whether enforceable Orange Book patents still block generic marketing at the time of ANDA acceptance and approval.

Generic entry mechanics that influence financial trajectory:

• ANDA timing: Filing can occur after certain legal triggers; launch depends on patent status and court outcomes.
• Injunction/settlement dynamics: Settlements can lead to authorized launch timelines.
• Geographic variation: Many markets do not mirror US Paragraph IV mechanics; instead, approvals and reimbursement decide entry speed.

What is the Orange Book status of Ferriprox patents and how does that map to generic launch risk?

Bottom line: Orange Book listings determine US generic design-around and litigation risk. The launch timeline in the US depends on (1) whether any Orange Book patents remain in force, (2) whether they are challenged, and (3) whether exclusivity is protected by regulatory exclusivity or court outcomes.

For market planning, the practical mapping is:

• Orange Book patent expirations drive when generic approval can translate into commercial substitution.
• Patent-by-patent enforcement determines whether generic launch can proceed immediately after expiry or gets delayed by litigation.

What patent litigation affects Ferriprox and how does it shift the revenue curve?

Bottom line: For legacy chelators, the major financial inflection is less about ongoing disputes and more about the sequence of generic introductions once patents expire. Litigation primarily affects the timing window of market entry and settlement-based launch dates.

Financial impact pathways:

• Delayed launches: Courts and settlements push generic entry past initial post-expiry windows.
• Design-around disputes: Even when patents expire, follow-on patents can force delayed approvals.

What biosimilar risk applies to Ferriprox?

Bottom line: Biosimilar risk is not applicable in the same way as it is for biologics because Ferriprox is a small-molecule product (deferiprone). The competitive risk is generic and follow-on drug competition rather than biosimilar substitution.

How do regulatory pathways and FDA status affect Ferriprox commercial access?

Bottom line: The financial trajectory depends on maintaining US market access through ongoing compliance and successful management of post-marketing requirements. Generic competition in the US also depends on FDA’s ANDA approvals and labeling, which determine substitution.

Key regulatory economics:

• Label stability: Changes in safety communications and indication scope can affect prescribing and payer coverage.
• ANDA bioequivalence acceptance: If generic manufacturers successfully demonstrate bioequivalence, substitution accelerates.

Which companies participate in the Ferriprox competitive landscape?

Bottom line: Ferriprox’s competitive field typically includes:

• The brand holder and associated regional marketing partners/licensors
• Generic manufacturers once patents and exclusivity permit
• Competing iron chelators (deferasirox products and deferoxamine brands/generics)

Market-share impact depends on:

• Tender pricing of each competing chelator
• Formulary positioning in major hematology centers
• Drug supply reliability

What generic entry risks exist for Ferriprox by business scenario?

Bottom line: Generic entry risks are highest where (1) formulation patents are weak or expire early, (2) payer systems move quickly to tenders, and (3) bioequivalence acceptance reduces uncertainty for generic sponsors.

Scenario mapping:

• Fast generic uptake: Core markets adopt generics quickly after approval due to procurement rules.
• Gradual erosion: Patient inertia and clinician preference slow switching.
• Segmented substitution: Some subgroups or dosing preferences preserve Ferriprox share longer.
• Tender-driven discontinuation: Local price wars can cause abrupt displacement even if clinical switching is slow.

What commercial risks and upside levers remain for Ferriprox?

Bottom line: Upside is mainly incremental through market expansion, patient retention, and label-focused positioning. Downside is driven by generic pricing, tender displacement, and competitor cycling.

Upside levers:

• Geographic expansion where oral chelation is not yet fully utilized
• Procurement contract wins that keep net pricing competitive
• Patient retention through stable safety monitoring protocols

Downside risks:

• Net price compression from low-cost generics
• Switching to once-daily oral competitors with stronger formulary positioning
• Regulatory or labeling restrictions that affect prescribing patterns

How does Ferriprox financial trajectory compare with other iron chelators (deferasirox and deferoxamine)?

Bottom line: Ferriprox typically faces stronger pricing pressure and lower convenience versus once-daily oral deferasirox, but can sustain share where clinical practice and procurement favor it or where switching frictions preserve established cohorts.

Comparison drivers:

• Dosing convenience (adherence and center protocol)
• Reimbursement and tender pricing
• Patient-level safety monitoring patterns
• Regional guideline emphasis

What Key Takeaways guide market and IP planning for Ferriprox?

• Ferriprox revenue is shaped by jurisdiction-specific exclusivity expirations and the pace of generic approvals and tender-based substitution.
• Net price compression and formulary substitution drive the erosion curve more than clinical differentiation after brand maturity.
• Competitive pressure comes primarily from deferasirox-based oral chelation and from local pricing power in procurement systems.
• Generic and follow-on risks depend on which patents remain enforceable by jurisdiction and whether formulation/method-of-use protections constrain substitution.
• Biosimilar risk is not a meaningful factor because Ferriprox is a small molecule (deferiprone).

FAQs

1. What drives payer switching from Ferriprox to deferasirox in chronic transfusional iron overload?
2. How quickly do deferiprone generics typically displace Ferriprox after approval in EU markets?
3. Which Ferriprox dosage forms face the highest formulation/IP design-around barriers?
4. What Orange Book patent expirations are most relevant to US generic launch timing for deferiprone?
5. How do hospital procurement tenders influence Ferriprox quarterly sales versus list price trends?

References

1. [No sources were provided in the prompt, and no cited materials are included.]